MARKET TALK: UK Regulator Says Consider Avandia Alternatives
26th Jul 2010 19:56
2:56 (Dow Jones) UK's Medicines and Healthcare Products Regulatory Agency weighs in on debate over safety of GlaxoSmithKline's (GSK) Avandia diabetes drug. "In view of the evidence of cardiovascular risk with [Avandia] our advice to healthcare professionals is to closely observe the current contrain
Read moreUS HOT STOCKS: Chico's, Genzyme, Hovnanian, Sanderson Farms -2
26th Jul 2010 18:07
Goldman Sachs added Chico's FAS Inc. (CHS, $10.02, -$0.22, -2.15%) to its conviction sell list, saying it sees the retailer's shares vulnerable to high expectations and a sharper-than-expected deceleration in momentum. Delta Petroleum Corp. (DPTR, $0.89, +$0.09, +10.68%) agreed to sell some non
Read moreMARKET TALK: Street Continues To Chew On Genzyme Deal Scenario
26th Jul 2010 17:45
12:45 (Dow Jones) Genzyme (GENZ) up 7.2% to $67 as Wall Street continues to mull over Friday's WSJ report of a takeover approach by France's Sanofi-Aventis (SNY). Lazard Capital believes a deal is possible and sees a price of $73 as reasonable. Baird puts the value in the low-to-mid $60 range with a
Read moreUS HOT STOCKS: FMC Tech, Genzyme, ON Semi, Sanderson Farms -2-
26th Jul 2010 15:03
FMC Technologies Inc.'s (FTI, $60.74, -$3.00, -4.71%) second-quarter earnings fell a less-than-feared 9.2% as revenue dropped but backlog increased sequentially at the maker of oil-and-gas drilling equipment. France's Sanofi-Aventis SA (SNY, $29.29, -$0.06, -0.20%) may not be the only large dru
Read moreGlaxo Admits Mistakes With Paid Medical Journal Supplement
26th Jul 2010 14:15
By Peter Loftus Of DOW JONES NEWSWIRES Drug maker GlaxoSmithKline PLC (GSK, GSK.LN) has admitted it wasn't fully transparent about its role in preparing a paid supplement to a medical journal last year, and that the supplement improperly discussed unapproved uses of its prostate-shrinking d
Read moreEuropean midday: Markets turn negative
26th Jul 2010 13:04
Europe's main markets are now lower as drugmakers weigh, but banks are still largely higher following the results of the European stress tests. GlaxoSmithKline dropped on rumours that the UK firm may be interested in buying US rival Genzyme. Novartis and Roche are also stuck in the red. After the
Read moreUPDATE: GlaxoSmithKline Pharmaceuticals 2Q Net Profit Rises 4%
26th Jul 2010 12:33
(Adds executive's comments on earnings, product launches) By Rumman Ahmed Of DOW JONES NEWSWIRES BANGALORE (Dow Jones)--GlaxoSmithKline Pharmaceuticals Ltd. (500660.BY) Monday reported a muted 4% rise in its second-quarter net profit, primarily because sales of vaccines were hurt due to
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
26th Jul 2010 11:56
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1056 GMT [Dow Jones] Ambrian analyst Mike Ward says he retains a buy on GlaxoSmithKline (GSK) after 2Q results showed benefit
Read moreMARKET TALK: Glaxo Gradually Returning To Growth - Ambrian
26th Jul 2010 11:56
1056 GMT [Dow Jones] Ambrian analyst Mike Ward says he retains a buy on GlaxoSmithKline (GSK) after 2Q results showed benefits of an increasingly diversified business whose strong pipeline has delivered a further five Phase III candidates. Says drug maker "is gradually returning to growth after a pe
Read moreGlaxoSmithKline Pharmaceuticals 2Q Net Profit INR1.29 Bln, Up 4%
26th Jul 2010 08:13
BANGALORE (Dow Jones)--GlaxoSmithKline Pharmaceuticals Ltd. (500660.BY) Monday posted a 4% rise in its second-quarter net profit to INR1.29 billion from INR1.24 billion a year earlier. The Indian unit of GlaxoSmithKline PLC (GSK.LN) said its sales for the three months ended June 30 rose 9% to IN
Read moreCerenis Therapeutics Raises EUR40 Mln; Former GlaxoSmithKline CEO Garnier Joins Board
26th Jul 2010 07:02
LONDON (Dow Jones)--Privately-held biotechnology company Cerenis Therapeutics SA said Monday that former GlaxoSmithKline PLC (GSK.LN) chief executive Jean-Pierre Garnier has joined its board, as it announced a EUR40 million fundraising to finance a mid-stage trial of an experimental heart drug.
Read moreWSJ: FDA Panelist's Vote On Glaxo Drug Raises Questions
23rd Jul 2010 22:41
By Alicia Mundy Of THE WALL STREET JOURNAL WASHINGTON (Dow Jones)--The Food and Drug Administration has asked investigators for the Department of Health and Human Services to look into whether there was a conflict of interest involving a panelist at a recent special meeting on the safety of
Read moreEU Panel Recommends Positive Opinion For Clopidogrel Teva Pharma
23rd Jul 2010 11:18
LONDON (Dow Jones)--The Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion for recommending the granting of marketing authorisations for Clopidogrel Teva Pharma B.V. (clopidogrel, as hydrobromide), from Teva Pharma B.V., for the prevention of ather
Read moreEMA Confirms Positive Benefit-Risk Balance Of Rotarix
22nd Jul 2010 16:38
LONDON (Dow Jones)--The European Medicines Agency or EMA said Thursday that following a review of the oral vaccine Rotarix, the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has concluded that the vaccine continues to have a positive benefit-risk balance and that
Read moreEMA Currently Reviewing Benefit- Risk Profile Of Avandia
22nd Jul 2010 16:22
LONDON (Dow Jones)--European Medicines Agency, announced Thursday it is currently reviewing Avandia or rosiglitazone to determine the impact of new data, from recent publications on the risk of cardiovascular problems, on the benefit- risk profile of these medicines. MAIN FACTS: -Prescribers
Read more